{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:07:43Z","timestamp":1753877263093,"version":"3.41.2"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The decision to use voriconazole for suspected COVID-19-associated pulmonary aspergillosis (CAPA) is based on clinical judgement weighed against concerns about its potential toxicity. We assessed the safety profile of voriconazole for patients with suspected CAPA by conducting a retrospective study of patients across two intensive care units. We compared changes in any liver enzymes or bilirubin and any new or increasing corrected QT interval (QTc) prolongation following voriconazole use to patient baseline to indicate possible drug effect.<\/jats:p>\n               <jats:p>In total, 48 patients with presumed CAPA treated with voriconazole were identified. Voriconazole therapy was administered for a median of 8 days (interquartile range [IQR] 5\u201322) and the median level was 1.86 mg\/L (IQR 1.22\u20132.94). At baseline, 2% of patients had a hepatocellular injury profile, 54% had a cholestatic injury profile, and 21% had a mixed injury profile. There were no statistically significant changes in liver function tests over the first 7 days after voriconazole initiation. At day 28, there was a significant increase in alkaline phospahte only (81\u2013122\u2009U\/L, P\u00a0=\u00a00.006), driven by changes in patients with baseline cholestatic injury. In contrast, patients with baseline hepatocellular or mixed injury had a significant decrease in alanine transaminase and aspartate transaminase. Baseline QTc was 437 ms and remained unchanged after 7 days of voriconazole therapy even after sensitivity analysis for concomitantly administered QT prolonging agents.<\/jats:p>\n               <jats:p>Therefore, at the doses used in this study, we did not detect evidence of significant liver or cardiac toxicity related to voriconazole use. Such information can be used to assist clinicians in the decision to initiate such treatment.<\/jats:p>","DOI":"10.1093\/mmy\/myad054","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:11:32Z","timestamp":1686193892000},"source":"Crossref","is-referenced-by-count":5,"title":["Assessing the safety profile of voriconazole use in suspected COVID-19-associated pulmonary aspergillosis\u2013a two-centre observational study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-7849","authenticated-orcid":false,"given":"Rahul","family":"Costa-Pinto","sequence":"first","affiliation":[{"name":"Department of Intensive Care, Austin Hospital , Heidelberg, Victoria, , Australia"},{"name":"Department of Critical Care, Department of Medicine, The University of Melbourne , Parkville, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Klink","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Austin Hospital , Heidelberg, Victoria, , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Rotherham","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Royal Melbourne Hospital , Melbourne, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padeepa","family":"Perera","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Royal Melbourne Hospital , Melbourne, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liam","family":"Finlay","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Royal Melbourne Hospital , Melbourne, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-578X","authenticated-orcid":false,"given":"Karen","family":"Urbancic","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Hospital , Heidelberg, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Vaz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Austin Hospital , Heidelberg, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Trubiano","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Austin Hospital , Heidelberg, Victoria , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1650-8939","authenticated-orcid":false,"given":"Rinaldo","family":"Bellomo","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Austin Hospital , Heidelberg, Victoria, , Australia"},{"name":"Department of Critical Care, Department of Medicine, The University of Melbourne , Parkville, Victoria , Australia"},{"name":"Department of Intensive Care, Royal Melbourne Hospital , Melbourne, Victoria , Australia"},{"name":"Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University , Melbourne, Victoria , Australia"},{"name":"Data Analytics Research and Evaluation Centre, The University of Melbourne and Austin Hospital , Melbourne , Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"5","key":"2023062313553699600_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2023062313553699600_bib2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2023062313553699600_bib3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1345\/aph.1H671","article-title":"Adverse effects of voriconazole: Analysis of the French Pharmacovigilance Database","volume":"41","author":"Eiden","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2023062313553699600_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"S1","key":"2023062313553699600_bib5","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1080\/13693780802227159","article-title":"Invasive aspergillosis in glucocorticoid-treated patients","volume":"47","author":"Lewis","year":"2009","journal-title":"Med Mycol"},{"issue":"6","key":"2023062313553699600_bib6","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.01657-09","article-title":"Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection","volume":"54","author":"Wang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2023062313553699600_bib7","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2023062313553699600_bib8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2023062313553699600_bib9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"2023062313553699600_bib10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2023062313553699600_bib11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/ctr.12834","article-title":"Adverse effects of voriconazole: Over a decade of use","volume":"30","author":"Levine","year":"2016","journal-title":"Clin Transplant"},{"key":"2023062313553699600_bib12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-017-2284-5","article-title":"Voriconazole-induced QT prolongation among hemato-oncologic patients: Clinical characteristics and risk factors","volume":"73","author":"Gueta","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2023062313553699600_bib13","first-page":"228","article-title":"Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone","volume":"74","author":"Mourad","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2023062313553699600_bib14","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","article-title":"COVID-19: Abnormal liver function tests","volume":"73","author":"Cai","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"2023062313553699600_bib15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"2023062313553699600_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/jof6020091","article-title":"COVID-19 associated pulmonary aspergillosis (CAPA)\u2014from immunology to treatment","volume":"6","author":"Arastehfar","year":"2020","journal-title":"J Fungi (Basel)"},{"issue":"1","key":"2023062313553699600_bib17","first-page":"1","article-title":"Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis","volume":"25","author":"Le\u00a0Dar\u00e9","year":"2021","journal-title":"Crit Care"},{"issue":"5","key":"2023062313553699600_bib18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41575-021-00426-4","article-title":"COVID-19 and liver disease: Mechanistic and clinical perspectives","volume":"18","author":"Marjot","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"S7","key":"2023062313553699600_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imj.15587","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021","volume":"51","author":"Chau","year":"2021","journal-title":"Intern Med J"},{"issue":"4","key":"2023062313553699600_bib20","doi-asserted-by":"crossref","first-page":"e216842","DOI":"10.1001\/jamanetworkopen.2021.6842","article-title":"Cardiac corrected QT interval changes among patients treated for COVID-19 infection during the early phase of the pandemic","volume":"4","author":"Rubin","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2023062313553699600_bib21","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"2023062313553699600_bib22","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3201\/eid2711.211174","article-title":"Multinational observational cohort study of COVID-19\u2013associated pulmonary Aspergillosis","volume":"27","author":"Janssen","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"2023062313553699600_bib23","doi-asserted-by":"crossref","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: A prospective study","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2023062313553699600_bib24","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for treatment of mechanically ventilated patients with COVID-19","volume":"73","author":"Somers","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2023062313553699600_bib25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bcp.14953","article-title":"Challenge in treating COVID-19 associate pulmonary aspergillosis: Supratherapeutic voriconazole levels","volume":"88","author":"Ekinci","year":"2022","journal-title":"Brit J Clinical Pharma"},{"issue":"2","key":"2023062313553699600_bib26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study","volume":"10","author":"Gangneux","year":"2022","journal-title":"The Lancet Respiratory Medicine"},{"issue":"5","key":"2023062313553699600_bib27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/MCC.0000000000000977","article-title":"COVID-19-associated pulmonary aspergillosis: An underdiagnosed or overtreated infection?","volume":"28","author":"Rouz\u00e9","year":"2022","journal-title":"Curr Opin Crit Care"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad054\/50536674\/myad054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/6\/myad054\/50685050\/myad054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/6\/myad054\/50685050\/myad054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T22:16:20Z","timestamp":1687644980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad054\/7191845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad054","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"type":"print","value":"1369-3786"},{"type":"electronic","value":"1460-2709"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,6]]},"article-number":"myad054"}}